TCL Archive As Amgen, Johnson & Johnson Battle Over Anemia Market, Medicare Enters The Fray December 13, 2002
TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive FDA Auditors Spend Two Weeks At Duke, Nevins Loses Position in Reorganization January 28, 2011
TCL Archive NCI Programs: Director Challenges Scientists To Develop Molecular “Fingerprints” Of Tumors December 4, 1998
